Zensar boosts healthcare expertise with BridgeView acquisition
NEW JERSEY, UNITED STATES — Zensar Technologies, a technology solutions company, has announced the full acquisition of BridgeView Life Sciences LLC, an information technology and operations provider specializing in life sciences.
The deal is part of Zensar’s ongoing effort to strengthen its Healthcare and Life Sciences (HLS) vertical, enhancing its offerings in pharmaceutical, biotechnology, and medical device sectors. Terms of the purchase remain undisclosed.
Strategic growth and market opportunity
With headquarters in Pune, India, Zensar Technologies operates across various countries, offering experience, engineering, and engagement technology solutions.
The acquisition of BridgeView, which boasts a skilled team with deep life sciences knowledge, positions Zensar to capitalize on the growing demand for Veeva-specific IT services, projected to reach $2 billion by 2025 according to Everest Group’s Veeva Services PEAK Matrix Assessment 2021.
“BridgeView Life Sciences brings a team of seasoned professionals with deep life sciences knowledge and a successful track record,” said Manish Tandon, CEO and Managing Director of Zensar Technologies.
“BridgeView’s expertise in biopharma cloud CRM, information management, analytics, and program management combined with their established client base will significantly enhance our HLS offerings and accelerate our go-to-market strategy.”
James Corbett and Mihales Karasavas, Co-founders of BridgeView Life Sciences LLC, commented on the acquisition, “Zensar’s global reach and digital expertise will help us offer more solutions and reach a wider audience. This synergy allows us to address customers’ transformational programs effectively, improving patient lives faster.”
Enhancing capabilities in life sciences
BridgeView Life Sciences brings to the table its “Preferred Services Partner” and “Services Partner” status with Veeva Systems’ Commercial Cloud and Development Cloud, respectively.
This, coupled with BridgeView’s partnerships with other industry leaders such as Reltio, Datavant, Snowflake, Salesforce, and IQVIA, significantly enhances Zensar’s capabilities in the life sciences sector.
“This acquisition deepens our services for existing clients and expands into new areas, especially for innovators and emerging pharma players underserved by technology,” said Anant Goenka, Vice-Chairman of RPG Enterprises and Zensar Technologies.
“It reflects our commitment to anticipating client and market needs and providing solutions to critical challenges.
